Thioredoxin reductase 1 haplotypes modify familial amyotrophic lateral sclerosis onset

Free Radical Biology and Medicine

Volumn 46, Issue 2, 2009, Pages 202-211

  Mitchell, John ^a   Morris, Alex ^a   de Belleroche, Jacqueline ^a  

^a Faculty of Medicine   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Familial amyotrophic lateral sclerosis; Free radicals; Haplotype analysis; Redox enzymes; Thioredoxin reductase; Thioredoxin system

Indexed keywords

THIOREDOXIN REDUCTASE 1;

ALLELE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BAYES THEOREM; CONTROLLED STUDY; EXON; FAMILIAL DISEASE; FEMALE; GENE FREQUENCY; GENE SEQUENCE; HAPLOTYPE; HUMAN; INTRON; MALE; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

AGE OF ONSET; AMYOTROPHIC LATERAL SCLEROSIS; BAYES THEOREM; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HAPLOTYPES; HUMANS; INTRONS; KAPLAN-MEIERS ESTIMATE; LINKAGE DISEQUILIBRIUM; MALE; OXIDATION-REDUCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS; THIOREDOXIN REDUCTASE 1;

EID: 58049211905     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2008.09.041     Document Type: Article

References (73)

1. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., Oregan J.P., Deng H.X., Rahmani Z., Krizus A., Mckennayasek D., Cayabyab A., Gaston S.M., Berger R., Tanzi R.E., Halperin J.J., Herzfeldt B., Vandenbergh R., Hung W.Y., Bird T., Deng G., Mulder D.W., Smyth C., Laing N.G., Soriano E., Pericakvance M.A., Haines J., Rouleau G.A., Gusella J.S., Horvitz H.R., and Brown R.H. Mutations in Cu/Zn superoxide-dismutase gene are associated with familial amyotrophic-lateral-sclerosis. Nature 362 (1993) 59-62
2. Pramatarova A., Figlewicz D.A., Krizus A., Han F.Y., Ceballospicot I., Nicole A., Dib M., Meininger V., Brown R.H., and Rouleau G.A. Identification of new mutations in the Cu/Zn superoxide-dismutase gene of patients with familial amyotrophic-lateral-sclerosis. Am. J. Hum. Genet. 56 (1995) 592-596
3. Pasinelli P., and Brown R.H. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci. 7 (2006) 710-723
4. Barber S.C., Mead R.J., and Shaw P.J. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim. Biophys. Acta 1762 (2006) 1051-1067
5. Andrus P.K., Fleck T.J., Gurney M.E., and Hall E.D. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 71 (1998) 2041-2048
6. Casoni F., Basso M., Massignan T., Gianazza E., Cheroni C., Salmona M., Bendotti C., and Bonetto V. Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: possible multifunctional role in the pathogenesis. J. Biol. Chem. 280 (2005) 16295-16304
7. Poon H.F., Hensley K., Thongboonkerd V., Merchant M.L., Lynn B.C., Pierce W.M., Klein J.B., Calabrese V., and Butterfield D.A. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med. 39 (2005) 453-462
8. Shibata N., Kawaguchi M., Uchida K., Kakita A., Takahashi H., Nakano R., Fujimura H., Sakoda S., Ihara Y., Nobukuni K., Takehisa Y., Kuroda S., Kokubo Y., Kuzuhara S., Honma T., Mochizuki Y., Mizutani T., Yamada S., Toi S., Sasaki S., Iwata M., Hirano A., Yamamoto T., Kato Y., Sawada T., and Kobayashi M. Protein-bound crotonaldehyde accumulates in the spinal cord of superoxide dismutase-1 mutation-associated familial amyotrophic lateral sclerosis and its transgenic mouse model. Neuropathology 27 (2007) 49-61
9. Kato S., Kato M., Abe Y., Matsumura T., Nishino T., Aoki M., Itoyama Y., Asayama K., Awaya A., Hirano A., and Ohama E. Redox system expression in the motor neurons in amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS, superoxide dismutase 1 (SOD1)-mutated familial ALS, and SOD1-mutated ALS animal models. Acta Neuropathol. 110 (2005) 101-112
10. Strey C.W., Spellman D., Stieber A., Gonatas J.O., Wang X.S., Lambris J.D., and Gonatas N.K. Dysregulation of stathmin, a microtubule-destabilizing protein, and up-regulation of Hsp25, Hsp27, and the antioxidant peroxiredoxin 6 in a mouse model of familial amyotrophic lateral sclerosis. Am. J. Pathol. 165 (2004) 1701-1718
11. Kirby J., Halligan E., Baptista M.J., Allen S., Heath P.R., Holden H., Barber S.C., Loynes C.A., Wood-Allum C.A., Lunec J., and Shaw P.J. Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS. Brain 128 (2005) 1686-1706
12. Malaspina A., Kaushik N., and de Belleroche J. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J. Neurochem. 77 (2001) 132-145
13. Gonzalez de Aguilar J.L., Niederhauser-Wiederkehr C., Halter B., De Tapia M., Di Scala F., Demougin P., Dupuis L., Primig M., Meininger V., and Loeffler J.P. Gene profiling of skeletal muscle in an amyotrophic lateral sclerosis mouse model. Physiol. Genomics 32 (2008) 207-218
14. Mansur K., Iwahashi Y., Kiryu-Seo S., Su Q., Namikawa K., Yodoi J., and Kiyama H. Up-regulation of thioredoxin expression in motor neurons after nerve injury. Mol. Brain Res. 62 (1998) 86-91
15. Nordberg J., and Arner E.S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med. 31 (2001) 1287-1312
16. Gasdaska P.Y., Gasdaska J.R., Cochran S., and Powis G. Cloning and sequencing of a human thioredoxin reductase. FEBS Lett. 373 (1995) 5-9
17. Mustacich D., and Powis G. Thioredoxin reductase. Biochem. J. 346 Pt 1 (2000) 1-8
18. Casso D., and Beach D. A mutation in a thioredoxin reductase homolog suppresses p53-induced growth inhibition in the fission yeast Schizosaccharomyces pombe. Mol. Gen. Genet. 252 (1996) 518-529
19. Ueno H., Kajihara H., Nakamura H., Yodoi J., and Nakamuro K. Contribution of thioredoxin reductase to T-cell mitogenesis and NF-kappaB DNA-binding promoted by selenite. Antioxid. Redox Signaling 9 (2007) 115-121
20. Xia L., Nordman T., Olsson J.M., Damdimopoulos A., Bjorkhem-Bergman L., Nalvarte I., Eriksson L.C., Arner E.S., Spyrou G., and Bjornstedt M. The mammalian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone: a novel mechanism for defense against oxidative stress. J. Biol. Chem. 278 (2003) 2141-2146
21. Anestal K., and Arner E.S. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J. Biol. Chem. 278 (2003) 15966-15972
22. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., Kawabata M., Miyazono K., and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 17 (1998) 2596-2606
23. Chae H.Z., Kang S.W., and Rhee S.G. Isoforms of mammalian peroxiredoxin that reduce peroxides in presence of thioredoxin. Methods Enzymol. 300 (1999) 219-226
24. Moriwaka F., Satoh H., Ejima A., Watanabe C., Tashiro K., Hamada T., Matsumoto A., Shima K., Yanagihara T., Fukazawa T., et al. Mercury and selenium contents in amyotrophic lateral sclerosis in Hokkaido, the northernmost island of Japan. J. Neurol. Sci. 118 (1993) 38-42
25. Bergomi M., Vinceti M., Nacci G., Pietrini V., Bratter P., Alber D., Ferrari A., Vescovi L., Guidetti D., Sola P., Malagu S., Aramini C., and Vivoli G. Environmental exposure to trace elements and risk of amyotrophic lateral sclerosis: a population-based case-control study. Environ. Res. 89 (2002) 116-123
26. Hill K.E., McCollum G.W., Boeglin M.E., and Burk R.F. Thioredoxin reductase activity is decreased by selenium deficiency. Biochem. Biophys. Res. Commun. 234 (1997) 293-295
27. Soares M.L., Coelho T., Sousa A., Batalov S., Conceicao I., Sales-Luis M.L., Ritchie M.D., Williams S.M., Nievergelt C.M., Schork N.J., Saraiva M.J., and Buxbaum J.N. Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease. Hum. Mol. Genet. 14 (2005) 543-553
28. Riazuddin S., Castelein C.M., Ahmed Z.M., Lalwani A.K., Mastroianni M.A., Naz S., Smith T.N., Liburd N.A., Friedman T.B., Griffith A.J., Riazuddin S., and Wilcox E.R. Dominant modifier DFNM1 suppresses recessive deafness DFNB26. Nat. Genet. 26 (2000) 431-434
29. Kunst C.B., Messer L., Gordon J., Haines J.L., and Patterson D. Genetic mapping of a modifier gene that delays ALS onset in a transgenic mouse model. Am. J. Hum. Genet. 67 (2000) 54
30. Giess R., Holtmann B., Braga M., Grimm T., Muller-Myhsok B., Toyka K.V., and Sendtner M. Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. Am. J. Hum. Genet. 70 (2002) 1277-1286
31. Orrell R.W., King A.W., Lane R.J.M., and Debelleroche J.S. Investigation of a null mutation of the CNTF gene in familial amyotrophic-lateral-sclerosis. J. Neurol. Sci. 132 (1995) 126-128
32. Al-Chalabi A., Scheffler M.D., Smith B.N., Parton M.J., Cudkowicz M.E., Andersen P.M., Hayden D.L., Hansen V.K., Turner M.R., Shaw C.E., Leigh P.N., and Brown R.H. Ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis. Ann. Neurol. 54 (2003) 130-134
33. Parton M.J., Broom W., Andersen P.M., Al-Chalabi A., Nigel Leigh P., Powell J.F., and Shaw C.E. D90A-SOD1 mediated amyotrophic lateral sclerosis: a single founder for all cases with evidence for a cis-acting disease modifier in the recessive haplotype. Hum. Mutat. 20 (2002) 473
34. Wu D.C., Re D.B., Nagai M., Ischiropoulo H., and Przedborski S. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc. Natl. Acad. Sci. USA 103 (2006) 12132-12137
35. Marden J.J., Harraz M.M., Williams A.J., Nelson K., Luo M., Paulson H., and Engelhardt J.F. Redox modifier genes in amyotrophic lateral sclerosis in mice. J. Clin. Invest. 117 (2007) 2913-2919
36. Sasieni P.D. From genotypes to genes: doubling the sample size. Biometrics 53 (1997) 1253-1261
37. Lewontin R.C. The Interaction of selection and linkage. I. General considerations, heterotic models. Genetics 49 (1964) 49-67
38. Hill W.G., and Robertson A. Linkage disequilibrium in finite populations. Theor. Appl. Genet. 38 (1968) 226-231
39. Terwilliger J.D., and Ott J. Handbook of Human Genetic Linkage (1994), Johns Hopkins Univ. Press, Baltimore
40. Stephens M., and Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73 (2003) 1162-1169
41. Servin B., and Stephens M. Imputation-based analysis of association studies: candidate regions and quantitative traits. PLoS Genet. 3 (2007) 1296-1308
42. Jeffreys H. Theory of Probability (1961), Oxford Univ. Press, London
43. Marchini J., Cutler D., Patterson N., Stephens M., Eskin E., Halperin E., Lin S., Qin Z.S., Munro H.M., Abecasis G.R., Donnelly P., and Consortium I.H. A comparison of phasing algorithms for trios and unrelated individuals. Am. J. Hum. Genet. 78 (2006) 437-450
44. Patenaude A., Murthy M.R.V., and Mirault M.E. Emerging roles of thioredoxin cycle enzymes in the central nervous system. Cell. Mol. Life Sci. 62 (2005) 1063-1080
45. Benhar M., Forrester M.T., Hess D.T., and Stamler J.S. Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. Science 320 (2008) 1050-1054
46. Wong C.M., Cheema A.K., Zhang L.H., and Suzuki Y.J. Protein carbonylation as a novel mechanism in redox signaling. Circ. Res. 102 (2008) 310-318
47. Wood Z.A., Poole L.B., and Karplus P.A. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 300 (2003) 650-653
48. Kim S.Y., Kim T.J., and Lee K.Y. A novel function of peroxiredoxin 1 (Prx-1) in apoptosis signal-regulating kinase 1 (ASK1)-mediated signaling pathway. FEBS Lett. 582 (2008) 1913-1918
49. Cronin S., Hardiman O., and Traynor B.J. Ethnic variation in the incidence of ALS-a systematic review. Neurology 68 (2007) 1002-1007
50. Nelson L.M. Epidemiology of ALS. Clin. Neurosci. 3 (1996) 327-331
51. Tanaka K., Watakabe A., and Shimura Y. Polypurine sequences within a downstream exon function as a splicing enhancer. Mol. Cell. Biol. 14 (1994) 1347-1354
52. Mcewen D.G., and Ornitz D.M. Regulation of the fibroblast growth factor receptor 3 promoter and intron I enhancer by Sp1 family transcription factors. J. Biol. Chem. 273 (1998) 5349-5357
53. Shibata A., Hattori M., Suda H., and Sakaki Y. Identification of cis-acting elements involved in an alternative splicing of the amyloid precursor protein (APP) gene. Gene 175 (1996) 203-208
54. Zuker M. On finding all suboptimal foldings of an RNA molecule. Science 244 (1989) 48-52
55. Rundlof A.K., Janard M., Miranda-Vizuete A., and Arner E.S.J. Evidence for intriguingly complex transcription of human thioredoxin reductase 1. Free Radic. Biol. Med. 36 (2004) 641-656
56. Ng C.J., Wadleigh D.J., Gangopadhyay A., Hama S., Grijalva V.R., Navab M., Fogelman A.M., and Reddy S.T. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 276 (2001) 44444-44449
57. Nadeau J.H. Modifier genes in mice and humans. Nat. Rev. Genet. 2 (2001) 165-174
58. Furukawa Y., and O'Halloran T.V. Amyotrophic lateral sclerosis mutations have the greatest destabilizing effect on the Apo- and reduced form of SOD1, leading to unfolding and oxidative aggregation. J. Biol. Chem. 280 (2005) 17266-17274
59. Jonsson P.A., Graffmo K.S., Andersen P.M., Brannstrom T., Lindberg M., Oliveberg M., and Marklund S.L. Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain 129 (2006) 451-464
60. Furukawa Y., Fu R.G., Deng H.X., Siddique T., and O'Halloran T.V. Disulfide cross-linked protein represents a significant fraction of ALS-associated Cu, Zn-superoxide dismutase aggregates in spinal cords of model mice. Proc. Natl. Acad. Sci. USA 103 (2006) 7148-7153
61. Matsumoto G., Stojanovic A., Holmberg C.I., Kim S., and Morimoto R.I. Structural properties and neuronal toxicity of amyotrophic lateral sclerosis-associated Cu/Zn superoxide dismutase 1 aggregates. J. Cell Biol. 171 (2005) 75-85
62. Atkin J.D., Farg M.A., Turner B.J., Tomas D., Lysaght J.A., Nunan J., Rembach A., Nagley P., Beart P.M., Cheema S.S., and Horne M.K. Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1. J. Biol. Chem. 281 (2006) 30152-30165
63. Lundstrom J., and Holmgren A. Protein disulfide-isomerase is a substrate for thioredoxin reductase and has thioredoxin-like activity. J. Biol. Chem. 265 (1990) 9114-9120
64. Uehara T., Nakamura T., Yao D.D., Shi Z.Q., Gu Z.Z., Ma Y.L., Masliah E., Nomura Y., and Lipton S.A. S-Nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 441 (2006) 513-517
65. Satoh M., Matter C.M., Ogita H., Takeshita K., Wang C.Y., Dorn G.W., and Liao J.K. Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation 115 (2007) 3197-3204
66. Deroo B.J., Hewitt S.C., Peddada S.D., and Korach K.S. Estradiol regulates the thioredoxin antioxidant system in the mouse uterus. Endocrinology 145 (2004) 5485-5492
67. Cereda C., Gabanti E., Corato M., de Silvestri A., Alimonti D., Cova E., Malaspina A., and Ceroni M. Increased incidence of FMO1 gene single nucleotide polymorphisms in sporadic amyotrophic lateral sclerosis. Amyotrophic Lateral Scler. 7 (2006) 227-234
68. Saeed M., Siddique N., Hung W.Y., Usacheva E., Liu E., Sufit R.L., Heller S.L., Haines J.L., Pericak-Vance M., and Siddique T. Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology 67 (2006) 771-776
69. Slowik A., Tomik B., Wolkow P.P., Partyka D., Turaj W., Malecki M.T., Pera J., Dziedzic T., Szczudlik A., and Figlewicz D.A. Paraoxonase gene polymorphisms and sporadic ALS. Neurology 67 (2006) 766-770
70. Lee Y.M., Park S.H., Shin D.I., Hwang J.Y., Park B., Park Y.J., Lee T.H., Chae H.Z., Jin B.K., Oh T.H., and Oh Y.J. Oxidative modification of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson disease. J. Biol. Chem. 283 (2008) 9986-9998
71. Mitsui A., Hamuro J., Nakamura H., Kondo N., Hirabayashi Y., Ishizaki-Koizumi S., Hirakawa T., Inoue T., and Yodoi J. Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid. Redox Signaling 4 (2002) 693-696
72. Takagi Y., Mitsui A., Nishiyama A., Nozaki K., Sono H., Gon Y., Hashimoto N., and Yodoi J. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc. Natl. Acad. Sci. USA 96 (1999) 4131-4136
73. Takagi Y., Hattori I., Nozaki K., Mitsui A., Ishikawa M., Hashimoto N., and Yodoi J. Excitotoxic hippocampal injury is attenuated in thioredoxin transgenic mice. J. Cereb. Blood Flow Metab. 20 (2000) 829-833